In this study, we have identified a novel protumorigenic FasL+PD‐L2+ neutrophil subset and have applied multiple complementary strategies to map the phenotype, mechanisms of induction, biologic function, and clinical relevance of these cells in the tumor environment of patients with GC. This evidence concerns the gene FASLG and gastric cancer.